Person: MENGÜÇ, BEDİRHAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
MENGÜÇ
First Name
BEDİRHAN
Name
3 results
Search Results
Now showing 1 - 3 of 3
Publication Efficacy of accelerated vaccination against hbv to achieve antibody formation in multiple sclerosis patients receiving anti-cd20 therapy(Wolters Kluwer Medknow Publications, 2023-09-01) KOÇ, EMİNE RABİA; SARIDAŞ, FURKAN; TURAN, ÖMER FARUK; Turan, Omer Faruk; Özkaya, Güven; ÖZKAYA, GÜVEN; Mengüç, Bedirhan; MENGÜÇ, BEDİRHAN; Minaz, Sema Nur; MİNAZ, SEMA NUR; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Bioistatistik Anabilim Dalı.; 0000-0002-0264-7284; 0000-0001-5945-2317; 0000-0003-0297-846X; HSB-2700-2023; JCO-1811-2023Aim:Ocrelizumab is a monoclonal antibody that has been approved for use in both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Since ocrelizumab acts on B cells, it also affects humoral immunity, thus reducing the vaccine response. In this study, we aimed to elucidate the relationship between the antibody response following rapid vaccination against hepatitis B virus (HBV) in multiple sclerosis (MS) patients receiving ocrelizumab treatment, and the time of vaccination.Materials and Methods:A total of 220 MS patients were included in this retrospective analysis. The patients' baseline HBV serostatuses (HbsAg, Anti-HbsAb, Anti-HbcAb), previous drug history for MS, whether they were vaccinated against HBV in the past, vaccination status before or after ocrelizumab treatment, and protective antibody titers according to vaccination times, occult HBV incidence and initiation of antiviral treatment were evaluated.Results:Forty-nine percent of MS patients using ocrelizumab were not vaccinated against HBV. The patients were divided into three groups according to their vaccination status as: individuals vaccinated in the past (7.3%, n = 16), vaccinated before treatment (4.5%, n = 10), and vaccinated after treatment (22.3%, n = 49). The antibody titers of the patients in the 6th month after ocrelizumab treatment were measured as 78 mIU/ml, 193 mIU/ml, and 0, respectively. The number of patients with occult HBV infection was 38.Conclusion:In patients with a suspected diagnosis of MS, HBV serostatus should be evaluated at the beginning and if necessary, patients should be vaccinated in the early period. Vaccinating patients at least 1 month before initiating multiple sclerosis treatment is more effective in terms of protective antibody formation.Publication Covid-19 infection as a possible risk factor for longitudinally extensive transverse myelitis!(Taylor & Francis Ltd, 2022-07-08) Mengüç, Bedirhan; MENGÜÇ, BEDİRHAN; Koç, Emine Rabia; KOÇ, EMİNE RABİA; Turan, Ömer Faruk; TURAN, ÖMER FARUK; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0002-0264-7284; A-7083-2015Introduction There is limited data about the neurological effects of Covid-19 in infected patients. In this report, we present 2 LETM cases that are possibly associated with Covid-19 infection. Methods Here, we present 2 cases that subsequently developed LETM following Covid-19 infection. The first case presented a finding of tetraparesis prominent in the lower extremities that started ten days after the Covid-19 infection. The second patient was admitted with paraparesis and urinary-stool retention on the 12th day from the onset of symptoms of Covid-19 infection. Results In these 2 cases, LETM developing following Covid'19 infection was associated with Covid-19 infection. Although Covid-19 PCR was negative in the CSF of both patients, the Covid-19 PCR test was positive in the samples taken from the oropharynx. Conclusion The mechanism of LETM caused by Covid-19 infection is not clearly known. However, both direct infection of the spinal cord and excessive inflammatory response to primary Covid-19 infection may cause spinal cord damage. Therefore, possible Covid-19-associated myelitis should be kept in mind in cases of long segment transverse myelitis grouped under the title of NMOSD and without any etiological factor.Publication Etiology, clinical characteristics and in-hospital mortality of status epilepticus: Single center experience(Galenos Yayınevi, 2023-03-01) Sarıdaş, Furkan; Mengüç, Bedirhan; Demir, Aylin Bican; Bora, İbrahim; SARIDAŞ, FURKAN; MENGÜÇ, BEDİRHAN; BİCAN DEMİR, AYLİN; BORA, İBRAHİM HAKKI; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0001-5945-2317; 0000-0001-6739-8605; HSB-2700-2023; V-7170-2017; JIJ-5059-2023; ENI-7759-2022Objective: Status epilepticus (SE) is a serious neurological emergency that can has high morbidity and mortality rates and requires prompt diagnosis and treatment. There are different etiologies and the prognosis varies multifactorially. The aim of this study was to reveal the etiological causes, clinical features and mortality rates of patients diagnosed with SE at our center.Methods: The records of 234 patients with a diagnosis of SE over the age of 18 who were followed up and treated at our center between 01.01.2015-01.01.2022 were evaluated retrospectively. Using the hospital information operating system database, we identified people hospitalized with an International Classification of Diseases 10th Revision code G41 for SE as the primary diagnosis. Demographic information, clinical characteristics, and discharge results were obtained from medical records.Results: One hundred-twenty (51.3%) female and 114 (48.7%) male patients were evaluated. The top 3 most common etiologic causes were: discontinuation of anti-seizure treatments without advice (n=82), cerebrovascular events (n=50), and meningitis or encephalitis (n=39). Motor seizures were detected in 183 (78.2%) patients, and non-motor seizures were detected in 51 (21.8%) patients. Seizures were suppressed by first-line treatment in 24 patients and by second -line treatments in 135 patients. Seventy-five patients whose seizures could not be suppressed were accepted as refractory SE and 9 died. The mean age of all patients was 55, and 63 of the patients died.Conclusion: In this study, clinical and demographic features, the etiological causes and in the hospital mortality rates of SE followed in a single center in the Turkish population were determined. The most common causes of patients diagnosed with SE were discontinuation of anti-seizure treatments without our recommendation, cerebrovascular diseases and central nervous system infections, respectively. In our center, no relationship was found between age and mortality. The in-hospital mortality rate was 3.9% for all patients (n=234) and 12% for patients with refractory SE (n=75).